Ikena Oncology (IKNA)
(Delayed Data from NSDQ)
$1.32 USD
0.00 (0.00%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.30 -0.02 (-1.52%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Ikena Oncology, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 175 | 157 | 232 | 162 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 3 | 3 | 4 | 3 | NA |
Total Current Assets | 179 | 160 | 237 | 166 | NA |
Net Property & Equipment | 2 | 3 | 2 | 1 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 5 | 4 | 2 | 1 | NA |
Total Assets | 192 | 172 | 248 | 168 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 2 | 2 | 2 | 2 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 9 | 8 | 6 | 5 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 9 | 17 | 21 | NA |
Total Current Liabilities | 14 | 22 | 27 | 28 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 8 | 35 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 1 | 0 | 0 | 206 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 22 | 25 | 40 | 269 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 452 | 362 | 353 | 10 | NA |
Retained Earnings | -282 | -214 | -145 | -111 | NA |
Other Equity | 0 | -1 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 170 | 147 | 208 | -101 | NA |
Total Liabilities & Shareholder's Equity | 192 | 172 | 248 | 168 | NA |
Total Common Equity | 170 | 147 | 208 | -101 | 0 |
Shares Outstanding | 48.20 | 36.20 | 35.90 | NA | NA |
Book Value Per Share | 3.52 | 4.06 | 5.79 | 0.00 | 0.00 |
Fiscal Year End for Ikena Oncology, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 175 | 197 | 157 | 138 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 4 | 3 | 3 |
Total Current Assets | NA | 179 | 201 | 161 | 141 |
Net Property & Equipment | NA | 2 | 3 | 3 | 3 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 5 | 4 | 4 | 3 |
Total Assets | NA | 192 | 215 | 172 | 152 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 4 | 2 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 9 | 11 | 6 | 5 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 2 | 4 |
Total Current Liabilities | NA | 14 | 19 | 12 | 14 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 33 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 22 | 60 | 15 | 17 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 452 | 418 | 403 | 364 |
Retained Earnings | NA | -282 | -263 | -246 | -228 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 170 | 155 | 157 | 135 |
Total Liabilities & Shareholder's Equity | NA | 192 | 215 | 172 | 152 |
Total Common Equity | 0 | 170 | 155 | 157 | 135 |
Shares Outstanding | 48.20 | 48.20 | 44.10 | 42.30 | 36.20 |
Book Value Per Share | 0.00 | 3.52 | 3.52 | 3.70 | 3.73 |